Docetaxel - Accord

Drug Profile

Docetaxel - Accord


Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Accord Healthcare
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer
  • Registered Colorectal cancer; Ovarian cancer

Most Recent Events

  • 08 Aug 2017 Registered for Colorectal cancer in Mexico (IV) (Accord Healthcare website, August 2017) before August 2017
  • 15 Jul 2015 Registered for Breast cancer (Combination therapy, Adjunctive treatment, Metastatic disease) in Mexico (IV)
  • 15 Jul 2015 Registered for Head and neck cancer (Combination therapy, Inoperable/Unresectable) in Mexico (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top